- Home
- DMF vs ADCT Comparison
DMF vs ADCT Comparison
Compare DMF & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMF
- ADCT
- Stock Information
- Founded
- DMF 1988
- ADCT 2011
- Country
- DMF United States
- ADCT Switzerland
- Employees
- DMF N/A
- ADCT N/A
- Industry
- DMF Finance/Investors Services
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- DMF Finance
- ADCT Health Care
- Exchange
- DMF Nasdaq
- ADCT Nasdaq
- Market Cap
- DMF 152.2M
- ADCT 131.8M
- IPO Year
- DMF N/A
- ADCT 2020
- Fundamental
- Price
- DMF $7.26
- ADCT $1.20
- Analyst Decision
- DMF
- ADCT Strong Buy
- Analyst Count
- DMF 0
- ADCT 5
- Target Price
- DMF N/A
- ADCT $7.75
- AVG Volume (30 Days)
- DMF 60.7K
- ADCT 360.3K
- Earning Date
- DMF 01-01-0001
- ADCT 03-27-2025
- Dividend Yield
- DMF 2.66%
- ADCT N/A
- EPS Growth
- DMF N/A
- ADCT N/A
- EPS
- DMF 0.15
- ADCT N/A
- Revenue
- DMF N/A
- ADCT $70,837,000.00
- Revenue This Year
- DMF N/A
- ADCT $11.56
- Revenue Next Year
- DMF N/A
- ADCT $17.03
- P/E Ratio
- DMF $45.13
- ADCT N/A
- Revenue Growth
- DMF N/A
- ADCT 1.84
- 52 Week Low
- DMF $5.37
- ADCT $1.22
- 52 Week High
- DMF $6.79
- ADCT $5.38
- Technical
- Relative Strength Index (RSI)
- DMF 58.25
- ADCT 27.88
- Support Level
- DMF $7.13
- ADCT $1.28
- Resistance Level
- DMF $7.29
- ADCT $1.68
- Average True Range (ATR)
- DMF 0.06
- ADCT 0.10
- MACD
- DMF -0.00
- ADCT -0.05
- Stochastic Oscillator
- DMF 76.00
- ADCT 0.75
About DMF BNY Mellon Municipal Income Inc.
BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.